Actinogen Medical Limited
Actinogen Medical (ACW) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company is dedicated to advancing its lead drug candidate, Xanamem, which targets the cortisol system to improve cognitive function in patients. Actinogen operates in the pharmaceutical sector, concentrating on research and development to address significant unmet medical needs in the field of dementia and age-related cognitive decline.